Raltitrexed enhanced antitumor effect of anlotinib in human esophageal squamous carcinoma cells on proliferation, invasiveness, and apoptosis

BACKGROUND: Anlotinib is a multi-targeted receptor tyrosine kinase inhibitor (TKI) which has exhibited encouraging clinical activity in advanced non-small cell lung cancer (NSCLC) and soft tissue sarcoma. Raltitrexed is well known to be effective in the treatment of colorectal cancer in China. The p...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhen, Hongchao, Tian, Jizheng, Li, Guangxin, Zhao, Pengfei, Zhang, Ying, Che, Juanjuan, Cao, Bangwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985835/
https://www.ncbi.nlm.nih.gov/pubmed/36870981
http://dx.doi.org/10.1186/s12885-023-10691-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985835/
https://www.ncbi.nlm.nih.gov/pubmed/36870981
http://dx.doi.org/10.1186/s12885-023-10691-y

Ejemplares similares